RBC Capital raised the firm’s price target on Neurocrine (NBIX) to $149 from $144 and keeps an Outperform rating on the shares. The firm’s analysis of the latest prescription trends suggests that Crenessity’s strong launch is likely to continue and that the drug should beat Q3 consensus expectations, the analyst tells investors in a research note. Shares look to have appreciated closer to fair value, perhaps reflecting increasing near-term optimism, RBC added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine’s Strong Market Performance and Promising Pipeline Justify Buy Rating
- Promising Growth and Strategic Positioning Drive Buy Rating for Neurocrine
- Neurocrine Biosciences Advances Schizophrenia Treatment with Phase 3 Study
- Neurocrine Biosciences Advances Phase 3 Study on Valbenazine for Cerebral Palsy Dyskinesia
- Neurocrine Biosciences’ Promising MDD Treatment Study: Key Insights for Investors